CarelonRx Segment — Reportable segments’ operating gain
Elevance Health CarelonRx Segment — Reportable segments’ operating gain decreased by 19.6% to $582.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.3%, from $602.00M to $582.00M. Over 4 years (FY 2021 to FY 2025), CarelonRx Segment — Reportable segments’ operating gain shows an upward trend with a 9.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher operating gain indicates strong profitability and effective management of both pharmacy costs and operational overhead.
Detailed definition
The operating profit generated by the CarelonRx segment, calculated as total operating revenue minus benefit expenses, p...
Peer comparison
Comparable to segment operating income reported by peers in the pharmacy benefit management and healthcare services industry.
elv_segment_carelonrx_reportable_segments_operating_gainHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $421.00M | $421.00M | $421.00M | $398.00M | $479.00M | $516.00M | $475.00M | $512.00M | $496.00M | $477.00M | $490.00M | $523.00M | $497.00M | $619.00M | $533.00M | $602.00M | $536.00M | $556.00M | $724.00M | $582.00M |
| QoQ Change | — | +0.0% | +0.0% | -5.5% | +20.4% | +7.7% | -7.9% | +7.8% | -3.1% | -3.8% | +2.7% | +6.7% | -5.0% | +24.5% | -13.9% | +12.9% | -11.0% | +3.7% | +30.2% | -19.6% |
| YoY Change | — | — | — | — | +13.8% | +22.6% | +12.8% | +28.6% | +3.5% | -7.6% | +3.2% | +2.1% | +0.2% | +29.8% | +8.8% | +15.1% | +7.8% | -10.2% | +35.8% | -3.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Elevance Health's carelonrx segment — reportable segments’ operating gain?
- Elevance Health (ELV) reported carelonrx segment — reportable segments’ operating gain of $582.00M in Q1 2026.
- How has Elevance Health's carelonrx segment — reportable segments’ operating gain changed year-over-year?
- Elevance Health's carelonrx segment — reportable segments’ operating gain decreased by 3.3% year-over-year, from $602.00M to $582.00M.
- What is the long-term trend for Elevance Health's carelonrx segment — reportable segments’ operating gain?
- Over 4 years (2021 to 2025), Elevance Health's carelonrx segment — reportable segments’ operating gain has grown at a 9.5% compound annual growth rate (CAGR), from $1.68B to $2.42B.
- What does carelonrx segment — reportable segments’ operating gain mean?
- The total operating profit earned by the CarelonRx pharmacy services segment.